Burcon Nutrascience Corporation has marked a significant achievement in the plant-based protein sector by successfully scaling up commercial production of its pea protein isolate at its Galesburg facility. This milestone, achieved in less than 90 days, is a critical step in Burcon's go-to-market strategy, enabling the company to meet increasing customer demand and tap into a market with a total addressable market estimated between US$215M and US$392M.
In a strategic move to bolster its financial standing, Burcon has announced a share consolidation program at a 20:1 ratio, set to commence on June 11, 2025. This initiative reflects the company's dedication to optimizing its capital structure and strengthening its market position.
The collaboration with ProMan in the third quarter of 2025 represents another leap forward for Burcon. This partnership allows Burcon to adopt a capital-light approach by leasing a protein production facility from ProMan, ensuring full control over its plant-based protein production. With production expected to start within 90 days, Burcon is confident in achieving its revenue targets, projecting first-year sales between $1M and $3M, and surpassing $10M in the second year, with profitability and positive cash flows anticipated by FY26.
Burcon's innovation in product commercialization is evident through its collaborations with Puratos to explore new applications for canola protein and the introduction of next-generation Peazazz® pea protein and Puratein® canola protein for egg replacement applications. The launch of Solatein™ sunflower protein isolate further diversifies Burcon's product offerings, catering to a broader market segment.
Financially, Burcon has shown progress with $0.06M in revenues from protein isolate sales and contract research services in 3Q25, a notable improvement from no revenues in the same quarter the previous year. Despite a net loss of $1.8M, or $0.01 per share, the company has demonstrated resilience, showing improvement from a net loss of $2.0M, or $0.02 per share, in the same period last year. With a pro-forma cash balance of approximately $10.0M following a successful rights offering, Burcon is well-equipped to continue its growth and innovation in the rapidly expanding plant-based protein market.
